Citadel Advisors’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.6M Buy
154,800
+117,867
+319% +$2.11M ﹤0.01% 5541
2025
Q4
$592K Sell
36,933
-144,514
-80% -$2.15M ﹤0.01% 8624
2025
Q3
$2.24M Buy
181,447
+36,778
+25% +$431K ﹤0.01% 5848
2025
Q2
$1.67M Buy
144,669
+13,319
+10% +$158K ﹤0.01% 6060
2025
Q1
$1.97M Buy
131,350
+23,281
+22% +$390K ﹤0.01% 5562
2024
Q4
$1.87M Sell
108,069
-18,708
-15% -$361K ﹤0.01% 5769
2024
Q3
$2.35M Buy
126,777
+49,242
+64% +$989K ﹤0.01% 5227
2024
Q2
$1.57M Sell
77,535
-313,866
-80% -$5.55M ﹤0.01% 5755
2024
Q1
$6.69M Buy
391,401
+33,501
+9% +$527K ﹤0.01% 3522
2023
Q4
$6.32M Buy
357,900
+113,130
+46% +$2.28M ﹤0.01% 3476
2023
Q3
$5.88M Buy
244,770
+45,389
+23% +$1.11M ﹤0.01% 3397
2023
Q2
$4.64M Buy
199,381
+119,717
+150% +$2.71M ﹤0.01% 3756
2023
Q1
$1.76M Sell
79,664
-119,347
-60% -$2.79M ﹤0.01% 5632
2022
Q4
$4.03M Sell
199,011
-58,736
-23% -$1.14M ﹤0.01% 4229
2022
Q3
$3.47M Buy
257,747
+63,340
+33% +$1.07M ﹤0.01% 4513
2022
Q2
$3.85M Buy
194,407
+109,255
+128% +$2.9M ﹤0.01% 4291
2022
Q1
$2.69M Sell
85,152
-87,360
-51% -$2.45M ﹤0.01% 5432
2021
Q4
$3.85M Buy
172,512
+104,903
+155% +$2.74M ﹤0.01% 4837
2021
Q3
$1.88M Buy
67,609
+13,076
+24% +$398K ﹤0.01% 6525
2021
Q2
$2.12M Sell
54,533
-30,833
-36% -$1.11M ﹤0.01% 6457
2021
Q1
$2.46M Sell
85,366
-264,445
-76% -$9.03M ﹤0.01% 5917
2020
Q4
$9.27M Sell
349,811
-214,536
-38% -$4.38M ﹤0.01% 2743
2020
Q3
$8.61M Sell
564,347
-738,377
-57% -$15.5M ﹤0.01% 2462
2020
Q2
$26.5M Buy
1,302,724
+1,194,742
+1,106% +$21.4M 0.01% 1260
2020
Q1
$1.12M Sell
107,982
-56,288
-34% -$1.57M ﹤0.01% 5139
2019
Q4
$6.19M Sell
164,270
-16,388
-9% -$736K ﹤0.01% 2820
2019
Q3
$8.42M Buy
180,658
+40,614
+29% +$1.89M ﹤0.01% 2423
2019
Q2
$7.32M Sell
140,044
-502,073
-78% -$29.4M ﹤0.01% 2569
2019
Q1
$44.3M Buy
642,117
+554,758
+635% +$37.2M 0.02% 758
2018
Q4
$5.21M Buy
87,359
+63,140
+261% +$5.45M ﹤0.01% 2719
2018
Q3
$2.81M Sell
24,219
-20,136
-45% -$2.27M ﹤0.01% 3842
2018
Q2
$5.6M Buy
44,355
+33,557
+311% +$4.08M ﹤0.01% 2605
2018
Q1
$1.17M Sell
10,798
-166,298
-94% -$18.4M ﹤0.01% 4567
2017
Q4
$19.4M Buy
177,096
+160,265
+952% +$16M 0.01% 1172
2017
Q3
$1.66M Sell
16,831
-153,989
-90% -$14.9M ﹤0.01% 3625
2017
Q2
$17.3M Buy
+170,820
New +$18.4M 0.01% 1083
2017
Q1
Sell
-14,485
Closed -$1.68M 7478
2016
Q4
$1.74M Sell
14,485
-27,560
-66% -$3.05M ﹤0.01% 3126
2016
Q3
$4.72M Buy
42,045
+31,491
+298% +$3.63M ﹤0.01% 2043
2016
Q2
$1.31M Buy
+10,554
New +$1.27M ﹤0.01% 3240
2015
Q4
Sell
-5,989
Closed -$686K 8752
2015
Q3
$598K Buy
+5,989
New +$651K ﹤0.01% 4545
2015
Q1
Sell
-3,338
Closed -$356K 8547
2014
Q4
$402K Buy
+3,338
New +$438K ﹤0.01% 5031
2014
Q3
Sell
-131,378
Closed -$20.3M 8136
2014
Q2
$21.9M Buy
131,378
+131,314
+205,178% +$23.4M 0.03% 752
2014
Q1
$13K Sell
64
-5,411
-99% -$1.02M ﹤0.01% 7424
2013
Q4
$1.05M Buy
5,475
+5,040
+1,159% +$938K ﹤0.01% 3183
2013
Q3
$74K Buy
435
+374
+613% +$58.1K ﹤0.01% 5555
2013
Q2
$9K Buy
+61
New +$8.64K ﹤0.01% 6259

Other funds holding CLB

Citadel Advisors's CLB Position: Q1 2026 in Review

Citadel Advisors increased its Core Laboratories (CLB) stake by 319% in Q1 2026, buying an estimated $2.11M and bringing the position to 154,800 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

Citadel Advisors first reported a position in CLB in Q2 2013 and has held it in 46 quarters since. The position peaked at $44.3M in Q1 2019. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.

  • Citadel Advisors held 154,800 shares of Core Laboratories worth $2.6M as of Q1 2026.
  • Citadel Advisors bought 117,867 Core Laboratories shares in Q1 2026, an estimated $2.11M.
  • Core Laboratories made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5541 holding.
  • Citadel Advisors first reported a position in Core Laboratories in Q2 2013 and has held it in 46 quarters since.
  • Citadel Advisors's Core Laboratories position peaked at $44.3M in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.